



Credit: Westend61 GmbH / Alamy Stock Photo

## Editorials

- 299** Red for danger in systematic reviews?  
*A Moore*

## Original research

- 301** Clinical pharmacy services in Germany: a national survey  
*C Schulz, A Fischer, W Vogt, K Leichenberg, U Warnke, A Liekweg, U Georgi, C Langebrake, T Hoppe-Tichy, F Dörje, H Knoth*

- 306** Availability of age-appropriate paediatric formulations in the Netherlands: the need in daily clinical practice remains  
*A van der Vossen, S Buljaç, K Akçay, J D Brugma, A Vulto, L Hanff*

- 313** Analysis of activities undertaken by ward-based clinical pharmacy technicians during patient hospital journey  
*A Abuelhana, L Ashfield, M G Scott, G F Fleming, N Sabry, S Farid, K Burnett*

- 320** Educational intervention to improve appropriate digoxin therapeutic drug monitoring: a quasi-experimental study  
*S Oncu, A Baskurt, B Senturk, O Aslan, T Kume, R Ucku, A Gelal*

- 325** Reducing the risk of non-sterility of aseptic handling in hospital pharmacies, part B: risk control  
*F A Boom, J M Ris, T Veenbaas, P P H Le Brun, D Touw*

- 331** Development of a sterile morphine hydrogel for the local treatment of painful skin ulcers  
*M M P M Jansen, V P H van Waas, J M Verzijl, D Burger*

- 336** Introduction to Bayesian statistics: a practical framework for clinical pharmacists  
*L R Van der Linden, J Hias, K Walgraeve, J Flamaing, I Isabel Spriet, J Tournoy*

- 341** Intravenous drug use in neonatal intensive care units  
*A De Basagoiti, A Fernández, S Mendiola, M De Miguel, E Guerra, B Loureiro, A Campino*

## Case reports

- 346** Successful treatment of interstitial pneumonitis with anakinra in a patient with adult-onset Still's disease  
*I Sollano-Sancho, B Rubio-Cebrian, M L de la Cruz, B San-Jose-Montano*


- 350** Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient  
*F J Navarro-Triviño, J M Llamas-Molina, A Ayen-Rodriguez, B Cancela-Diez, R Ruiz-Villaverde*

- 353** A patient with ulcerative colitis treated with a combination of vedolizumab and tofacitinib  
*P Taberner Bonastre, G Torres Vicente, M Cano-Marron, E Sese Abizanda, T Dalila Volta Pardo, J Antoni Schoenenberger-Arnaiz*

## News

- 356** EAHP news: EAHP's survey on hazardous medicinal products  
*S Kohl*

- 357** EU news: Spread awareness, stop resistance – getting ready for WAAW and EAAD  
*S Kohl*

 This article has been chosen by the Editor to be of special interest or importance and is freely available online.

 This article has been made freely available under the BMJ Journals open access scheme. See <https://authors.bmj.com/open-access>

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics  
Member since 2008  
JME00225  
[www.publicationethics.org](http://www.publicationethics.org)

 **recycle**  
When you have finished with this magazine please recycle it.